0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Combination of intrahepatic TARE and extrahepatic TACE to treat HCC patients with extrahepatic artery supply: A case series

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          The aim of this study was to report the safety and tumor response rate of combined transarterial radioembolization (TARE) through the intrahepatic arteries and transarterial chemoembolization (TACE) through the extrahepatic feeding arteries (EHFA) in patients with hepatocellular carcinoma (HCC).

          Methods

          Patients with HCC, who had both intrahepatic and extrahepatic arterial supply visible on preinterventional multiphase CT and were treated between 2016 and 2021 with a combination of TACE and TARE on the same nodule, were retrospectively included. Epidemiological, clinical, biological, and radiological characteristics were recorded. Safety and tumor response were assessed at 6 months.

          Results

          Nine patients (8 men, median age 62 years [IQR: 54–72 years]) were included. Seven patients had previous treatments on the target nodule (TARE: 5; TACE: 2). The median longest axis (LA) of the lesion was 70 mm (IQR: 60–79 mm). Three patients had portal vein invasion (VP3). The EHFA originated from the right diaphragmatic artery ( n = 6), the right adrenal artery ( n = 2), and the left gastric artery ( n = 1). The LA of the tumor portion treated with TACE was 47 mm (range: 35–64 mm). The ratio between the LA of the entire lesion and the LA treated with TACE was 1.44 (range: 1.27–1.7). One major complication occurred: acute on chronic liver failure. Median follow-up was 23 months (range: 16–29 months). Seven patients underwent further treatment: on the same lesion ( n = 2), on newly appeared nodules ( n = 2), and systemic treatment ( n = 3). At 6-month follow-up, seven patients showed a local objective response. Time-to-progression was 13 (3.5–19) months.

          Conclusion

          The combination of TARE and extrahepatic TACE for HCC with both intrahepatic and extrahepatic arterial supplies seems feasible and safe. Further studies are needed to validate the effectiveness of these preliminary results.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: not found
          • Article: not found

          EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Toxicity and response criteria of the Eastern Cooperative Oncology Group.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update

              There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.
                Bookmark

                Author and article information

                Contributors
                Journal
                Res Diagn Interv Imaging
                Res Diagn Interv Imaging
                Research in Diagnostic and Interventional Imaging
                Elsevier
                2772-6525
                10 March 2024
                March 2024
                10 March 2024
                : 9
                : 100042
                Affiliations
                [a ]Department of Interventional Radiology, hôpital Avicenne (AP-HP), Bobigny, France
                [b ]Department of Radiology, hôpital Henri-Mondor (AP-HP), Créteil, France
                [c ]Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France
                [d ]Department of Nuclear Medicine, hôpital Henri-Mondor (AP-HP), Créteil, France
                [e ]Department of Hepatology, hôpital Henri-Mondor (AP-HP), Créteil, France
                [f ]Inserm IMRB U955, équipe 8, université Paris-Est Créteil, Créteil, France
                Author notes
                [* ]Corresponding author. lorenzo.pescatori@ 123456aphp.fr
                Article
                S2772-6525(24)00003-6 100042
                10.1016/j.redii.2024.100042
                11265365
                39076578
                be954d05-0777-4a2d-83da-a9a880852914
                © 2024 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 19 October 2023
                : 24 February 2024
                Categories
                Original Article

                tace,tare,extrahepatic artery,hcc
                tace, tare, extrahepatic artery, hcc

                Comments

                Comment on this article